CN1198609C - 用白蛋白稳定的紫杉醇在制备用于治疗实体瘤的药物方面的应用和由此获得的药物 - Google Patents
用白蛋白稳定的紫杉醇在制备用于治疗实体瘤的药物方面的应用和由此获得的药物 Download PDFInfo
- Publication number
- CN1198609C CN1198609C CNB011192585A CN01119258A CN1198609C CN 1198609 C CN1198609 C CN 1198609C CN B011192585 A CNB011192585 A CN B011192585A CN 01119258 A CN01119258 A CN 01119258A CN 1198609 C CN1198609 C CN 1198609C
- Authority
- CN
- China
- Prior art keywords
- paclitaxel
- medicine
- tumor
- albumin
- abi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 108010088751 Albumins Proteins 0.000 title claims abstract description 7
- 102000009027 Albumins Human genes 0.000 title claims abstract description 7
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 48
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 48
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 239000006185 dispersion Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 239000004531 microgranule Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000011859 microparticle Substances 0.000 abstract description 3
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 20
- 239000000243 solution Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 210000000436 anus Anatomy 0.000 description 4
- 238000001361 intraarterial administration Methods 0.000 description 4
- 230000036770 blood supply Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000003090 iliac artery Anatomy 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 238000011127 radiochemotherapy Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000013010 hypopharyngeal carcinoma Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000MI001107A ITMI20001107A1 (it) | 2000-05-18 | 2000-05-18 | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| ITMI2000A001107 | 2000-05-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1324613A CN1324613A (zh) | 2001-12-05 |
| CN1198609C true CN1198609C (zh) | 2005-04-27 |
Family
ID=11445079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011192585A Ceased CN1198609C (zh) | 2000-05-18 | 2001-05-18 | 用白蛋白稳定的紫杉醇在制备用于治疗实体瘤的药物方面的应用和由此获得的药物 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6652884B2 (https=) |
| EP (1) | EP1155692B1 (https=) |
| JP (1) | JP2001354559A (https=) |
| KR (2) | KR20010105248A (https=) |
| CN (1) | CN1198609C (https=) |
| AT (1) | ATE267594T1 (https=) |
| AU (1) | AU781517B2 (https=) |
| BR (1) | BR0102040A (https=) |
| CA (1) | CA2345482A1 (https=) |
| DE (1) | DE60103453T2 (https=) |
| DK (1) | DK1155692T3 (https=) |
| ES (1) | ES2221874T3 (https=) |
| HU (1) | HU229909B1 (https=) |
| IL (1) | IL142674A0 (https=) |
| IT (1) | ITMI20001107A1 (https=) |
| MX (1) | MXPA01004980A (https=) |
| NO (1) | NO330511B1 (https=) |
| NZ (1) | NZ511201A (https=) |
| PT (1) | PT1155692E (https=) |
| RU (1) | RU2270003C2 (https=) |
| TR (1) | TR200101353A3 (https=) |
| ZA (1) | ZA200103755B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940929A (zh) * | 2006-11-06 | 2015-09-30 | 阿布拉科斯生物科学有限公司 | 紫杉醇和白蛋白纳米颗粒联合贝伐单抗对抗癌症 |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070092563A1 (en) * | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| HUP9701554D0 (en) * | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| ITMI20020681A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| CN103405405A (zh) * | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
| CN1925874B (zh) * | 2002-12-09 | 2014-12-17 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| US20040224019A1 (en) * | 2004-03-03 | 2004-11-11 | Adi Shefer | Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs |
| AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| AU2006284657B2 (en) | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| KR101420445B1 (ko) | 2005-08-31 | 2014-07-16 | 아브락시스 바이오사이언스, 엘엘씨 | 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물 |
| WO2007069272A2 (en) * | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| WO2008109163A1 (en) | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc. | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| JP5579057B2 (ja) | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | 再発性癌の処置のための方法および組成物 |
| MX2010011165A (es) * | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
| KR101090505B1 (ko) * | 2008-12-30 | 2011-12-06 | 최은아 | 난담반을 포함하는 암 예방 및 치료용 조성물 |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| NZ717490A (en) | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| BR112012030909A2 (pt) | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| JP6038123B2 (ja) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP6216721B2 (ja) | 2011-12-14 | 2017-10-18 | アブラクシス バイオサイエンス， エルエルシー | 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| CN105209035A (zh) * | 2013-03-13 | 2015-12-30 | 阿布拉科斯生物科学有限公司 | 治疗儿童实体瘤的方法 |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| PL3998069T3 (pl) | 2015-06-29 | 2025-03-31 | Abraxis Bioscience, Llc | Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych |
| EP3505183B1 (en) | 2016-08-26 | 2022-03-30 | Tetsuji Okuno | Microvascular blood flow decreasing agent and use thereof |
| TWI660728B (zh) | 2018-02-09 | 2019-06-01 | National Chiao Tung University | 胺基喹唑啉衍生物及其醫藥組合物與用途 |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| JP7832108B2 (ja) | 2019-10-28 | 2026-03-17 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| CN120919082A (zh) * | 2025-10-16 | 2025-11-11 | 天津医科大学总医院 | 一种负载蛋白药物的GelMA微球、制备方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2678833B1 (fr) * | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| BR9405798A (pt) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| BRPI9810945B8 (pt) * | 1997-06-27 | 2021-05-25 | Abraxis Bioscience Inc | formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas |
| WO2000006152A1 (en) | 1998-07-30 | 2000-02-10 | Novopharm Biotech, Inc. | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
-
2000
- 2000-05-18 IT IT2000MI001107A patent/ITMI20001107A1/it unknown
-
2001
- 2001-04-17 US US09/835,384 patent/US6652884B2/en not_active Expired - Lifetime
- 2001-04-18 IL IL14267401A patent/IL142674A0/xx active IP Right Grant
- 2001-04-19 NZ NZ511201A patent/NZ511201A/xx not_active IP Right Cessation
- 2001-04-20 AU AU38765/01A patent/AU781517B2/en not_active Expired
- 2001-04-24 JP JP2001126061A patent/JP2001354559A/ja active Pending
- 2001-04-27 PT PT01110509T patent/PT1155692E/pt unknown
- 2001-04-27 AT AT01110509T patent/ATE267594T1/de active
- 2001-04-27 DK DK01110509T patent/DK1155692T3/da active
- 2001-04-27 EP EP01110509A patent/EP1155692B1/en not_active Expired - Lifetime
- 2001-04-27 DE DE60103453T patent/DE60103453T2/de not_active Expired - Lifetime
- 2001-04-27 ES ES01110509T patent/ES2221874T3/es not_active Expired - Lifetime
- 2001-04-27 CA CA002345482A patent/CA2345482A1/en not_active Abandoned
- 2001-05-09 ZA ZA200103755A patent/ZA200103755B/xx unknown
- 2001-05-15 TR TR2001/01353A patent/TR200101353A3/tr unknown
- 2001-05-16 NO NO20012409A patent/NO330511B1/no not_active IP Right Cessation
- 2001-05-17 HU HU0102039A patent/HU229909B1/hu unknown
- 2001-05-17 KR KR1020010026970A patent/KR20010105248A/ko not_active Ceased
- 2001-05-17 MX MXPA01004980A patent/MXPA01004980A/es active IP Right Grant
- 2001-05-17 RU RU2001113688/15A patent/RU2270003C2/ru active
- 2001-05-18 BR BR0102040-4A patent/BR0102040A/pt not_active Application Discontinuation
- 2001-05-18 CN CNB011192585A patent/CN1198609C/zh not_active Ceased
-
2008
- 2008-09-26 KR KR1020080094590A patent/KR20080091747A/ko not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940929A (zh) * | 2006-11-06 | 2015-09-30 | 阿布拉科斯生物科学有限公司 | 紫杉醇和白蛋白纳米颗粒联合贝伐单抗对抗癌症 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1198609C (zh) | 用白蛋白稳定的紫杉醇在制备用于治疗实体瘤的药物方面的应用和由此获得的药物 | |
| JP5175017B2 (ja) | 有効成分の経口吸収を改善するための粒子状担体 | |
| CN1139380A (zh) | 控释制剂 | |
| WO2008016664A2 (en) | Compositions and methods for treating cancer with dacarbazine nanoemulsions | |
| BR112020011774A2 (pt) | composições farmacêuticas com duração de liberação selecionada | |
| JP2004507451A (ja) | アポトーシス誘導性化学療法剤の投与による癌の治療のための方法及び組成物 | |
| EP1667656A1 (en) | Compositions and methods for delivery of biologically active agents | |
| Yu et al. | Antitumor effect of intratumoral administration of fluorouracil/epinephrine injectable gel in C3H mice | |
| Wang et al. | An absorbable local anesthetic matrix provides several days of functional sciatic nerve blockade | |
| RU2485956C2 (ru) | Новая композиция для лечения побочных эффектов противораковой терапии | |
| WO2001076559A1 (en) | Method 0f administration of paclitaxel-plasma protein formulation | |
| CN110870918A (zh) | 包含氨基酸类营养素和抗肿瘤化疗药物的药物组合物及其应用 | |
| JPH07165582A (ja) | 免疫抗癌剤の抗癌効果増強剤 | |
| JP3442866B2 (ja) | 難水溶性薬物含有徐放性製剤 | |
| CN114681613B (zh) | 一种原位成胶化疗免疫药物组合物及其制备方法 | |
| CN115414343B (zh) | α-酮戊二酸及其衍生物的应用、防治皮肤肿瘤的药物 | |
| CN112007025B (zh) | 米拉贝隆在制备预防和/或治疗恶性肿瘤的药物中的应用 | |
| RU2676279C1 (ru) | Стабильное противоопухолевое лекарственное средство, способ его получения и применения | |
| CN103127514B (zh) | 一种可体内注射的药物缓释栓剂 | |
| CN102389571B (zh) | 一种可体内注射的药物缓释栓剂 | |
| HK1040368B (en) | Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby | |
| CN1410058A (zh) | 地非三唑在制备治疗恶性肿瘤疾病药剂中的应用 | |
| CN113230420A (zh) | 包含亚甲蓝类活体染料的水基乳剂、该乳剂的应用以及包含该乳剂的药物组合物 | |
| CA2469613A1 (en) | Process for affecting neurologic progression | |
| JPWO1992005797A1 (ja) | 化学・免疫学的抗癌物質製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ABRAXIS BIOSCIENCE INC Free format text: FORMER OWNER: ACS DOBFAR SPA Effective date: 20070713 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070713 Address after: American California Patentee after: American Bioscience, Inc. Address before: Italy triy Arnold Patentee before: Acs Dobfar SPA |
|
| ASS | Succession or assignment of patent right |
Owner name: ABRAXIS BIOSCIENCE CO., LTD. Free format text: FORMER OWNER: ABRAXIS BIOSCIENCE Effective date: 20090821 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090821 Address after: American California Patentee after: Abraxis Bioscience, LLC Address before: American California Patentee before: American Bioscience, Inc. |
|
| IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20171109 Decision number of declaring invalidation: 33779 Granted publication date: 20050427 |
|
| IW01 | Full invalidation of patent right |